Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» This Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative Treatment
This Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative Treatment
This Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative Treatment
Submitted by
admin
on August 29, 2024 - 11:10am
Source:
Motley Fool
News Tags:
IPOs
Artiva
autoimmune diseases
cell therapy
AlloNK
Headline:
This Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative Treatment
snippet:
Artiva has two-bagger potential in the eyes of multiple Wall Street analysts.
Its cell therapies could provide a much more efficient treatment of autoimmune diseases.
Artiva faces years of hurdles, but investors could make out handsomely if it is successful.
Do Not Allow Advertisers to Use My Personal information
